Jeffrey Low, MD

Jeffrey Low is a respected name in the venture capital industry, particularly in the field of therapeutics, healthcare, and technology. He is an MD by training with deep expertise, combining his medical knowledge and experience in growth to invest in the next generation of life sciences companies. Mr. Low holds an MBA from Harvard Business School, an AB in Molecular and Cellular Biology from Harvard University, and completed his Doctor of Medicine (MD) from Yale University School of Medicine.

Before joining Andreessen Horowitz in 2016 as a Deal Team member, Mr. Low worked with Google Capital (now CapitalG), where he was involved in growth healthcare investments. Before that, he had a stint with Novartis Venture Fund and dRx Capital, where he focused on biotech and digital health sectors, investing in game-changing health startups like Omada Health and Lemonaid Health. At a16z, he has completed investments in Accolade, Citiizen, Devoted Health, InSitro, Jungla, The One Health Company, TwoXAR, and five stealth companies.

Throughout his career, Mr. Low has served as a board observer on many prominent companies, including Apeel Sciences, Cardiogram, Freenome, Omada Health, and Rigetti Computing, among others. He is a third-generation San Franciscan and an avid squash player. Mr. Low was named to the Forbes 30 Under 30 list in Venture Capital in 2019.